Positive Phase III Results Show Xofluza Significantly Reduces the Transmission of Influenza VirusesBusiness Wire • 18h
Positive phase III results show Xofluza significantly reduces the transmission of influenza virusesGlobeNewsWire • 18h
Mindpeak Announces Collaboration With Roche to Enhance Cancer Diagnostics Through AIBusiness Wire • Monday
FDA approves OCREVUS ZUNOVO™ as the first and only twice-a-year 10-minute subcutaneous injection for people with relapsing and progressive multiple sclerosisGlobeNewsWire • Monday
Roche Gets FDA Approval for Subcutaneous Formulation of TecentriqZacks Investment Research • 09/13/24
FDA Approves Ocrevus Zunovo™ as the First and Only Twice-a-Year 10-Minute Subcutaneous Injection for People With Relapsing and Progressive Multiple SclerosisBusiness Wire • 09/13/24
Roche Stock to Benefit From Accu-Chek Smartguide Launch in EuropeZacks Investment Research • 09/13/24
FDA approves Roche's Tecentriq Hybreza, the first and only subcutaneous anti-PD-(L)1 cancer immunotherapyGlobeNewsWire • 09/13/24
FDA Approves Genentech's Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer ImmunotherapyBusiness Wire • 09/12/24
Roche Stock Down on Concerns of Side-Effects From Its Obesity DrugZacks Investment Research • 09/12/24
Roche: Why I'm Not Concerned About Slight Sell-Off On Weight Loss Drug Safety DataSeeking Alpha • 09/11/24
Roche opens Pharma Research and Development Center in Basel to accelerate scientific innovationGlobeNewsWire • 09/10/24
Lunit Joins Roche's Digital Pathology Open Environment to Advance Cancer Biomarker TestingPRNewsWire • 09/09/24
The Zacks Analyst Blog Amazon, Roche, GE Aerospace, Canterbury Park and NVEZacks Investment Research • 09/09/24
Stratipath and Roche Join Forces to Help Expand Access to AI-Powered Precision DiagnosticsGlobeNewsWire • 09/09/24
Roche advances AI-driven cancer diagnostics by expanding its digital pathology open environmentPRNewsWire • 09/09/24
Roche's fenebrutinib demonstrated near-complete suppression of disease activity and disability progression for up to 48 weeks in patients with relapsing multiple sclerosisGlobeNewsWire • 09/04/24